Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Core Viewpoint - Jasper Therapeutics is focused on developing briquilimab, a novel antibody therapy targeting mast cell-driven diseases, with promising clinical results reported for chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) [1][2]. Clinical Development - Briquilimab demonstrated a complete response rate of 89% in the BEACON study for CSU patients receiving 240 mg and 360 mg single doses [2][3]. - In the open-label extension study, 73% of patients maintained a complete response at 12 weeks with 180 mg dosed every 8 weeks [3]. - The SPOTLIGHT study showed a 92% complete response rate in CIndU patients at the 180 mg dose, with rapid onset of action observed [3]. Safety and Tolerability - Briquilimab has shown a favorable safety profile, with no dose-limiting toxicities reported and adverse events being low grade and infrequent [3][4]. - Ongoing investigations are being conducted to understand the lack of UAS7 reduction in certain cohorts, with no safety signals observed that would impede further dosing [3][6]. Financial Performance - For the second quarter of fiscal 2025, Jasper reported a net loss of $26.7 million, with a basic and diluted net loss per share of $1.74 [6][10]. - Research and development expenses for the quarter were $21.2 million, while general and administrative expenses totaled $5.9 million [6][10]. Corporate Restructuring - The company implemented a workforce reduction of approximately 50% to focus resources on its urticaria programs and preserve capital [6]. - Non-mast cell focused clinical and preclinical programs have been halted to concentrate on briquilimab development [6]. Cash Position - As of June 30, 2025, Jasper had cash and cash equivalents totaling $39.5 million, down from $71.6 million at the end of 2024 [6][13].